To evaluate the hepatic safety of elinzanetant in women experiencing hot flashes related to menopause or endocrine therapy for breast cancer, focusing on the outcomes of clinical trials.
Key Findings:
Elinzanetant 120 mg shows a low risk of liver problems, indicating its potential safety profile.
No serious liver issues were reported during clinical trials, supporting its hepatic safety.
Mild liver changes were comparable between elinzanetant and placebo groups, suggesting no significant adverse effects.
Interpretation:
The findings suggest that elinzanetant does not pose a significant risk for drug-induced liver injury, supporting its use as a treatment for VMS, with implications for clinical practice.
Limitations:
The studies primarily involved healthy volunteers and postmenopausal women with moderate-to-severe VMS, which may limit generalizability.
Long-term effects beyond the clinical trials are still being evaluated, and potential biases in study design should be considered.
Conclusion:
Elinzanetant is a safe option for managing hot flashes in the studied populations, with no need for routine liver monitoring post-approval, although ongoing vigilance is recommended.
